Practice Patterns in the Use of Anti-Tumor Necrosis Factor Alpha Agents in the Management of Crohn’s Disease: A US National Practice Survey Comparing Experts and Non-Experts

摘要

Background The US Food and Drug Administration currently approves three types of anti-tumor necrosis factor α (anti-TNFα) therapy for treatment of moderate to severe Crohn’s disease. There are no guidelines to clarify which of the drugs may be better suited to individual clinical scenarios.